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Effects of oncological treatments on semen quality in
patients with testicular neoplasia or lymphoproliferative
disorders
Cataldo Di Bisceglie, Angela Bertagna, Emanuela R Composto, Fabio Lanfranco, Matteo Baldi, Giovanna Motta,
Anna M Barberis, Emanuela Napolitano, Elena Castellano and Chiara Manieri
Pretherapy sperm cryopreservation in youngmen is currently included in good clinical practice guidelines for cancer patients. The aim
of this paper is to outline the effects of different oncological treatments on semen quality in patients with testicular neoplasia or
lymphoproliferative disorders, based on an8-year experience of theCryopreservation Centre of a large public hospital. Two hundred and
sixty-one patients with testicular neoplasia and 219 patients with lymphoproliferative disorders who underwent chemotherapy and/or
radiotherapy and pretherapy semen cryopreservation were evaluated. Sperm and hormonal parameters (follicle-stimulating hormone
(FSH), luteinizing hormone (LH), testosterone, inhibinB levels) were assessed prior to and6, 12, 18, 24 and36months after the end of
cancer treatment. At the time of sperm collection, baseline FSH level and sperm concentration were impaired to a greater extent in
patients with malignant testicular neoplasias than in patients with lymphoproliferative disorders. Toxic effects on spermatogenesis
were still evident at 6 and 12months after the end of cancer therapies, while an improvement of seminal parameters was observed after
18months. In conclusion, an overall increase in sperm concentrationwas recorded about 18months after the end of cancer treatments
in the majority of patients, even if it was not possible to predict the evolution of each single case ‘a priori ’. For this reason, pretherapy
semen cryopreservation should be considered in all young cancer patients.
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INTRODUCTION
In the last 10 years, following the increased success rate of cancer
treatments, great efforts have been made to improve quality of life
in survivors, including fertility preservation in young patients.
Because of their gonadotoxic effects, chemo- and radiotherapy can
temporarily or permanently compromise fertility. The development
of several assisted reproduction techniques, including semen cryopre-
servation, has brought effective and qualitative changes in this field.1,2
Every year 6500 men aged 15–39 years develop cancer in Italy. In
particular, malignant testicular neoplasias (TN) represent 16% of all
new cancer diagnoses (incidence of 10.2/100 000 inhabitants), fol-
lowed by Hodgkin lymphomas and non-Hodgkin lymphomas
(respective incidence of 5.0/100 000 and 6.2/100 000). Thanks to
modern cancer therapies, these neoplasms are usually associated with
good prognosis. Chemotherapy with platinum and its derivatives,
surgical treatments and radiotherapy lead to an overall 5-year survival
rate of 90%–95% for TN, 92% for Hodgkin lymphoma and 71% for
non-Hodgkin lymphoma.3,4
At the same time, the increase in the overall survival rate of patients
with germinal and hematological neoplasias treated with chemo- and
radiotherapies is accompanied by an increase in infertility rates.5,6
Indeed, oncological treatments present severe gonadotoxic effects on
both germ and Leydig cells.7–9 Of note, in a significant percentage of
patients (20%–50%) spermatogenesis is impaired even before cancer
treatments, probably due to the malignancy itself.10 The recovery of
normal spermatogenesis after treatmentmay require several years, and
mainly depends on three factors: initial sperm count, type and dose of
specific oncological treatments and patient age.
These data justify the increasing efforts in identifying prevention
and treatment strategies to preserve reproductive functions in young
men with malignancies. In several countries, sperm cryopreservation
before gonadotoxic therapy is a common practice for the preservation
of reproductive potential in cancer treatment survivors, and specific
procedures are well established.11–13
The aim of this study was to evaluate the effects of chemotherapy
and radiotherapy on seminal and reproductive hormones parameters
in patients with malignant testicular tumors or lymphoproliferative
disorders.
MATERIALS AND METHODS
Four hundred and eighty patients who referred to the Sperm
Cryopreservation Centre of San Giovanni Battista Hospital, Turin,
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Italy, fromOctober 2000 toApril 2008 andwho completed a follow-up
period of 36 months were included in the study. Of these, 261 patients
were affected by TN (mean age6s.e.m.: 27.960.6 years) and were
evaluated after unilateral orchiectomy (pT1 stage in 51% of cases,
pT2 in 44% and pT3 in 5%): 154 patients (59%) (TNCT group) were
diagnosed with non-seminomatous TN and were treated only with
chemotherapy (consisting of 2–4 cycles of bleomycin, etoposide, and
cisplatin); 107 patients (41%) (TNRT group) were affected by semi-
noma and were treated with radiotherapy only (20–30 Gy dose, direc-
ted to the paraaortic/paracaval lymph nodes); 219 patients had
malignant lymphoproliferative disorders (LDs; mean age6s.e.m.:
29.161.2 years). Of these, 125 (57%) (LDCT group) presented with
Hodgkin lymphoma and were treated only with chemotherapy (con-
sisting of 4–6 cycles of doxorubicin, bleomycin, vinblastine, and
dacarbazine). Ninety-four (43%) (LDRT group) presented with
non-Hodgkin lymphoma and were treated with chemotherapy (con-
sisting of 3–6 cycles of cyclophosphamide, doxorubicin, vincristine,
and prednisone/prednisolone plus rituximab in B-cell lymphomas)
and radiotherapy (30–36 Gy dose directed towards the chest or abdo-
men). No detrimental effects of therapy on ejaculation were present in
all the patients.
We included in the study only patients with similar diseases and
comparable treatments (only chemotherapy or radiotherapy; both
chemotherapy and radiotherapy) to limit confounding factors.
Patients with TN who underwent retroperitoneal lymph node dissec-
tion or surveillance were excluded. Similarly, patients with TN or LD
who underwent second line treatment for relapse were excluded.
In all patients, semen parameters (including sperm concentration,
progressive motility and sperm morphology) along with hormonal
levels (including follicle-stimulating hormone (FSH), luteinizing hor-
mone (LH), testosterone and inhibin B) were assessed at the time of
semen cryopreservation before cancer treatments and 6, 12, 18, 24 and
36 months after the end of treatment.
FSH and LH levels were evaluated by immunoradiometric assay,
testosterone levels by radioimmunoassay and inhibin B levels by
enzyme-linked immunosorbent assay. Semen parameters were eva-
luated following World Health Organization guidelines for semen
analysis.14
Seminal and hormonal parameters were compared in each group
and among groups during follow-up. Results are expressed as mean6
s.e.m. Because data do not follow a normal distribution, statistical
analyses were performed using Mann–Whitney non-parametric test
for unrelated samples and Wilcoxon test for related samples. Results
were considered statistically significant for P,0.05.
RESULTS
When the four groups of patients were compared, the TNCT group
presented the lowest baseline sperm concentration (P,0.001, MW).
LDCT and LDRT presented similar baseline levels, that were higher
than the other two groups (P,0.001, MW). TNRT group showed the
highest baseline FSH levels (P,0.001, MW), while FSH levels in the
other three groups were similar. Baseline values of inhibin B were
higher in LDCT and LDRT groups than TNCT and TNRT groups
(P,0.001, MW; Tables 1–4).
Baseline LH and testosterone levels, sperm progressive motility and
normal morphology did not show any difference in the four groups
(Table 5).
Patients of the TNCT group showed a reduction in sperm concen-
tration (P,0.05,W) at 6 and 12months after treatment, followed by a
return to baseline levels at 18, 24 and 36 months after treatment
(Table 1 and Figure 1). In this group, FSH levels increased after
chemotherapy and continued to be persistently elevated until month
24 (P,0.05, W; Table 1 and Figure 2). Inhibin B mirrored FSH
variations, being reduced until month 24 (P,0.05, W; Table 1 and
Figure 3).
Sperm concentration of TNRT patients underwent no changes dur-
ing the entire 36months follow-up (Table 2 and Figure 1). FSH raised
at month 6 (P,0.01, W) and returned to baseline values by month 12
(Table 2 and Figure 2), while a significant reduction of inhibin B was
shown only at 12 months (P,0.001, W; Table 2 and Figure 3).
The LDCT group showed a reduction in sperm concentration at
months 6 and 12 (P,0.05, W) and a recovery at months 18, 24 and 36
(Table 3 and Figure 1). FSH levels were increased at months 6, 12, 18
and 24 (P,0.01, W; Table 3 and Figure 2). Inhibin B levels showed a
reduction at month 6 (P,0.001, W), but no other statistically signifi-
cant variations (compared to baseline values) at the other time points
(Table 3 and Figure 3).
LDRT group presented a reduction of sperm concentration at
months 6 and 12 (P,0.01, W), followed by the return to baseline
values starting at months 18, 24 and 36 (Table 4 and Figure 1). FSH
increased frommonth 6 (P,0.05,W) and returned to baseline levels at
months 18 and 36 (Table 4 and Figure 2); on the other hand, inhibin B
showed a reduction at month 6 (P,0.01, W) and a return to baseline
levels at month 18 (Table 4 and Figure 3).
The comparison of hormonal and seminal parameters during fol-
low-up period in the four groups, showed the lowest sperm concen-
tration in TNCT group (P,0.05, MW) at months 6 and 12.
Afterwards, no differences in the increase of sperm concentration were
recorded among the four groups when compared to baseline values
(Figure 1).
As described before, FSH increase in TNCT and LDCT groups was
prolonged until month 24, while in TNRT and LDRT groups, FSH
levels returned to baseline values at months 12 and 18–36, respectively
(Figure 2).
Inhibin B concentrations remained similar in the four groups at
months 6, 12, 18 and 24, while atmonth 36, inhibin B levels were lower
in TNCT group than TNRT group (P,0.05, MW; Figure 3).
LH and testosterone levels, sperm progressive motility and normal
morphology did not show any variations at each time point in the
different groups.
Table 1 Follicle-stimulating hormone (FSH) and inhibin B levels and sperm concentration (mean6s.e.m.) in patients with TNCT in baseline
conditions and 6, 12, 18, 24 and 36months after the end of the oncological treatments: in parentheses percent of patients with normal values
Month after oncological treatments
Normal value 0 6 12 18 24 36
FSH (mIU ml21) ,10 6.560.5 (79%) 20.462.2 (19%) 18.561.8 (21%) 14.562.9 (44%) 18.363.2 (30%) 13.561.5 (50%)
Inhibin B (pg ml21) o80 56.562.8 (22%) 36.263.8 (3%) 38.364.6 (10%) 58.3610.3 (24%) 37.866.2 (11%) 52.266.8 (21%)
Sperm concentration (million ml21) o20 33.163.2 (62%) 19.566.2 (32%) 15.563.5 (28%) 48.3614.0 (62%) 42.8610.2 (60%) 42.7613.2 (61%)
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DISCUSSION
Malignancies and cancer treatments can temporarily or permanently
impair male fertility. Predictive markers for gonadal function after
oncological treatments are not currently available. The type and dura-
tion of treatment can influence post-treatment recovery, even if very
different results have been reported in patients undergoing the same
therapeutic schemes.15 Because innovative fertility preservation tech-
niques (i.e., semen cryopreservation) exist, this aspect should always
be evaluated and discussed with patients before the initiation of a
cancer treatment, taking into consideration adequate preventive mea-
sures and multidisciplinary collaborations with the entire medical
staff.
This study shows that baseline FSH levels and sperm concentration
were impaired to a greater extent in TN than LD patients. These data
are in agreement with previous studies.16,17 The lowest baseline sperm
concentration was detected in the TNCT group, while the TNRT
group showed higher baseline FSH levels when compared to the
TNCT group, likely because of the presence of elevated b-hCG levels
with FSH (and spermatogenesis) inhibition in some TNCT patients
with non-seminomatous germ cell tumors.18 On the other hand, base-
line inhibin B levels were higher in LDCT and LDRT groups than in
TNCT and TNRT groups.
In transversal and longitudinal trials, some authors evaluated hor-
monal fluctuations in patients with germ cell tumors after chemother-
apy.19 A compensated impairment of the Leydig cell function could be
observed up to 60 months following chemotherapy. Meanwhile, 68%
of the patients showed increased FSH levels, indicating that spermato-
genesis is more severely impaired than steroidogenesis.
The present follow-up data indicate that the increase of FSH levels
in TNCT and LDCT was prolonged until month 24, while in TNRT
and LDRT groups, FSH levels returned to baseline values at months 12
and 18–36, respectively. Inhibin B concentrations remained similar in
the four groups at months 6, 12, 18 and 24, while inhibin B levels were
lower in TNCT group at month 36 than in TNRT group. On the other
hand, no difference in testosterone and LH levels was detected after
cancer therapy.
Gandini et al.20 investigated chemotherapy and radiotherapy short-
and long-term effects on spermatogenesis in 166 patients with TNwith
the aim to identify possible correlations among pre-treatment sperm
parameters, tumor histotype, treatment and post-treatment sper-
matogenesis’ modifications. A significant worsening of sperm para-
meters was observed in 71 patients who underwent chemotherapy,
and the most important impairments were detected 3 months after
the end of treatment. The reduction was even more pronounced at 6
Table 2 Follicle-stimulating hormone (FSH) and inhibin B levels and sperm concentration (mean6s.e.m.) in patients with TNRT in baseline
conditions and 6, 12, 18, 24 and 36months after the end of the oncological treatments: in parentheses percent of patients with normal values
Month after oncological treatments
Normal value 0 6 12 18 24 36
FSH (mIU ml21) ,10 9.560.5 (55%) 15.962.0 (34%) 11.661.4 (54%) 11.262.8 (50%) 8.460.9 (67%) 8.761.6 (70%)
Inhibin B (pg ml21) o80 58.563.5 (24%) 49.667.4 (16%) 44.064.8 (11%) 59.766.3 (25%) 55.665.8 (23%) 71.566.5 (40%)
Sperm concentration (million ml21) o20 46.064.5 (66%) 36.266.4 (47%) 43.868.1 (63%) 56.8616.3 (80%) 54.069.6 (82%) 52.3611.3 (84%)
Table 3 Follicle-stimulating hormone (FSH) and inhibin B levels and sperm concentration (mean6s.e.m.) in patients with LDCT in baseline
conditions and 6, 12, 18, 24 and 36months after the end of the oncological treatments: in parentheses percent of patients with normal values
Month after oncological treatments
Normal value 0 6 12 18 24 36
FSH (mIU ml21) ,10 5.060.3 (92%) 11.361.5 (50%) 8.661.7 (57%) 12.263.9 (49%) 10.962.1 (52%) 8.462.1 (73%)
Inhibin B (pg ml21) o80 94.864.8 (50%) 47.265.3 (12%) 63.269.3 (38%) 74.1616.3 (40%) 66.3610.0 (45%) 73.3612.5 (55%)
Sperm concentration (million ml21) o20 76.366.8 (73%) 32.868.3 (46%) 21.965.6 (36%) 43.9613.5 (64%) 50.3615.9 (80%) 48.168.8 (83%)
Table 4 Follicle-stimulating hormone (FSH) and inhibin B levels and sperm concentration (mean6s.e.m.) in patients with LDRT in baseline
conditions and 6, 12, 18, 24 and 36months after the end of the oncological treatments: in parentheses percent of patients with normal values
Month after oncological treatments
Normal value 0 6 12 18 24 36
FSH (mIU ml21) ,10 4.760.4 (96%) 9.861.3 (58%) 12.162.7 (50%) 4.861.0 (80%) 11.864.0 (55%) 5.861.3 (83%)
Inhibin B (pg ml21) o80 107.269.5 (59%) 63.068.7 (33%) 52.1615.3 (20%) 107.7623.6 (67%) 58.2622.3 (50%) 74.3615.8 (60%)
Sperm concentration (million ml21) o20 74.9612.1 (75%) 47.3612.5 (57%) 32.6622.3 (45%) 102.7630.6 (73%) 49.7635.1 (77%) 69.0624.6 (78%)
Table 5 Baseline luteinizing hormone (LH) and testosterone levels, sperm progressive motility and normal morphology (mean6s.e.m.) in the
four groups of patients
LH (mIU ml21) Testosterone (ng ml21) Progressive motility (%) Normal morphology (%)
TNCT 4.060.3 5.460.2 44.561.7 19.461.0
TNRT 3.460.2 4.760.2 48.861.9 21.761.3
LDCT 3.660.2 4.460.2 40.461.7 17.660.9
LDRT 2.960.3 4.860.2 42.763.0 24.962.4
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months after the end of treatment in 95 patients who had undergone
radiotherapy.
In our study, TNCT, LDCT and LDRT groups showed a significant
reduction in sperm concentration at months 6 and 12 after treatment;
no significant changes were noticed in TNRT group; sperm motility
and morphology showed no differences among the four groups. An
improvement of sperm concentration was observed after 18months in
patients who underwent cancer therapy.
Our results confirmed the great impact that chemo- and radio-
therapy have on semen quality and sex hormone profile, and, at the
same time, the absence of reliable predictors of fertility status after
treatment. Recovery of sperm concentration was recorded 18 months
after the end of cancer treatments in the majority of the cases, even if it
is was not possible to predict the evolution of each single case ‘a priori’.
In conclusion, counselling on fertility preservation techniques and
andrological follow-up should be offered to all patients in the setting
of a specialized cryopreservation centre, in order to monitor semen
and hormone modifications over time and to identify possible differ-
ences in the evolution of specific malignancies and treatment schemes.
Because it is often difficult to have long time follow-ups, it is advisable
that cryopreservation centres create an information network in order
to allow the comparison of the single centres’ experience. This would
in turn facilitate future choices regarding the best therapeutic options
to be offered to cancer patients, and point out new preventive mea-
sures in the field of fertility preservation.
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